{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:34:20Z","timestamp":1790048060295,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T00:00:00Z","timestamp":1400544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1245\/s10434-014-3794-3","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T16:16:03Z","timestamp":1400516163000},"page":"3978-3984","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma"],"prefix":"10.1245","volume":"21","author":[{"given":"Yinin","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Smolkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice Y.","family":"Neese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,20]]},"reference":[{"key":"3794_CR1","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1189\/jlb.1212631","volume":"94","author":"MK Callahan","year":"2013","unstructured":"Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol. 2013;94:41\u201353.","journal-title":"J Leukoc Biol."},{"key":"3794_CR2","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1200\/JCO.2008.17.3161","volume":"26","author":"CL Slingluff Jr","year":"2008","unstructured":"Slingluff CL Jr, Petroni GR, Olson W, et al. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol. 2008;26:4973\u201380.","journal-title":"J Clin Oncol."},{"key":"3794_CR3","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","volume":"19","author":"CL Slingluff Jr","year":"2013","unstructured":"Slingluff CL Jr, Lee S, Zhao F, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013;19:4228\u201338.","journal-title":"Clin Cancer Res."},{"key":"3794_CR4","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1056\/NEJMoa1012863","volume":"364","author":"DJ Schwartzentruber","year":"2011","unstructured":"Schwartzentruber DJ, Lawson DH, Richards JM, et al. Gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119\u201327.","journal-title":"N Engl J Med."},{"key":"3794_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00002371-200409000-00006","volume":"27","author":"EM Woodson","year":"2004","unstructured":"Woodson EM, Chianese-Bullock KA, Wiernasz CJ, et al. Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine. J Immunother. 2004;27:380\u20138.","journal-title":"J Immunother."},{"key":"3794_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/01.cji.0000171314.00924.2b","volume":"28","author":"KA Chianese-Bullock","year":"2005","unstructured":"Chianese-Bullock KA, Woodson EM, Tao H, et al. Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2. J Immunother. 2005;28:412\u20139.","journal-title":"J Immunother."},{"key":"3794_CR7","first-page":"3342","volume":"54","author":"A Barth","year":"1994","unstructured":"Barth A, Hoon DS, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res. 1994;54:3342\u20135.","journal-title":"Cancer Res."},{"key":"3794_CR8","doi-asserted-by":"publisher","first-page":"8130","DOI":"10.1128\/IAI.73.12.8130-8135.2005","volume":"73","author":"J Rowe","year":"2005","unstructured":"Rowe J, Yerkovich ST, Richmond P, et al. Th2-associated local reactions to the acellular diphtheria\u2013tetanus\u2013pertussis vaccine in 4- to 6-year-old children. Infect Immun. 2005;73:8130\u20135.","journal-title":"Infect Immun."},{"key":"3794_CR9","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/CJI.0b013e3181e311ac","volume":"33","author":"CL Slingluff","year":"2010","unstructured":"Slingluff CL, Petroni GR, Smolkin ME, et al. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete Freund\u2019s adjuvant for multipeptide melanoma vaccines. J Immunother. 2010;33:630\u20138.","journal-title":"J Immunother."},{"key":"3794_CR10","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s00262-013-1435-5","volume":"62","author":"EP Salerno","year":"2013","unstructured":"Salerno EP, Shea SM, Olson WC, et al. Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund\u2019s adjuvant, with or without peptide. Cancer Immunol Immunother. 2013;62:1149\u201359.","journal-title":"Cancer Immunol Immunother."},{"key":"3794_CR11","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1158\/1078-0432.CCR-09-1544","volume":"15","author":"CL Slingluff Jr","year":"2009","unstructured":"Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009;15:7036\u201344.","journal-title":"Clin Cancer Res."},{"key":"3794_CR12","doi-asserted-by":"publisher","first-page":"795876","DOI":"10.1186\/1479-5876-8-79","volume":"8","author":"JT Schaefer","year":"2010","unstructured":"Schaefer JT, Patterson JW, Deacon DH, et al. Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med. 2010;8:795876\u20139.","journal-title":"J Transl Med."},{"key":"3794_CR13","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1200\/JCO.2010.33.8053","volume":"29","author":"CL Slingluff Jr","year":"2011","unstructured":"Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol. 2011;29:2924\u201332.","journal-title":"J Clin Oncol."},{"key":"3794_CR14","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/archderm.1987.01660320095019","volume":"123","author":"JC Bystryn","year":"1987","unstructured":"Bystryn JC, Rigel D, Friedman RJ, Kopf A. Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol. 1987;123:1053\u20135.","journal-title":"Arch Dermatol."},{"key":"3794_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","volume":"19","author":"SA Rosenberg","year":"1996","unstructured":"Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19:81\u20134.","journal-title":"J Immunother Emphasis Tumor Immunol."},{"key":"3794_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u201323.","journal-title":"N Engl J Med."},{"key":"3794_CR17","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/nrc3153","volume":"11","author":"P Sharma","year":"2011","unstructured":"Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11:805\u201312.","journal-title":"Nat Rev Cancer."},{"key":"3794_CR18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","volume":"11","author":"JD Wolchok","year":"2010","unstructured":"Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155\u201364.","journal-title":"Lancet Oncol."},{"key":"3794_CR19","first-page":"341","volume":"342","author":"A Weinberg","year":"2010","unstructured":"Weinberg A, Levin MJ. VZV T cell\u2013mediated immunity. Curr Top Microbiol Immunol. 2010;342:341\u201357.","journal-title":"Curr Top Microbiol Immunol."},{"key":"3794_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nm.3105","volume":"19","author":"Y Hailemichael","year":"2013","unstructured":"Hailemichael Y, Dai Z, Jaffarzad N, et al. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med. 2013;19:465\u201372.","journal-title":"Nat Med."},{"key":"3794_CR21","first-page":"456","volume":"53","author":"E Bloemena","year":"1993","unstructured":"Bloemena E, Gall H, Ransom JH, et al. Delayed-type hypersensitivity reactions to tumor-associated antigens in colon carcinoma patients immunized with an autologous tumor cell\/bacillus Calmette-Gu\u00e9rin vaccine. Cancer Res. 1993;53:456\u20139.","journal-title":"Cancer Res."},{"key":"3794_CR22","first-page":"1347","volume":"6","author":"ML Disis","year":"2000","unstructured":"Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2\/neu peptide immunization. Clin Cancer Res. 2000;6:1347\u201350.","journal-title":"Clin Cancer Res."},{"key":"3794_CR23","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.4049\/jimmunol.1201540","volume":"189","author":"S van Duikeren","year":"2012","unstructured":"van Duikeren S, Fransen MF, Redeker A, et al. Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors. J Immunol. 2012;189:3397\u2013403.","journal-title":"J Immunol."},{"issue":"15","key":"3794_CR24","doi-asserted-by":"publisher","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","volume":"19","author":"CL Slingluff Jr","year":"2013","unstructured":"Slingluff CL Jr, Lee S, Zhao F, et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res. 2013;19(15):4228\u20134238.","journal-title":"Clin Cancer Res."},{"key":"3794_CR25","doi-asserted-by":"publisher","first-page":"e22616","DOI":"10.4161\/onci.22616","volume":"2","author":"S van Duikeren","year":"2013","unstructured":"van Duikeren S, Arens R. Predicting the efficacy of cancer vaccines by evaluating T-cell responses. Oncoimmunology. 2013;2:e22616.","journal-title":"Oncoimmunology."},{"key":"3794_CR26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1086\/651453","volume":"201","author":"JI Cohen","year":"2010","unstructured":"Cohen JI, Hohman P, Fulton R, et al. Kinetics of serum cytokines after primary or repeat vaccination with the smallpox vaccine. J Infect Dis. 2010;201:1183\u201391.","journal-title":"J Infect Dis."},{"key":"3794_CR27","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1086\/382510","volume":"189","author":"MT Rock","year":"2004","unstructured":"Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE Jr. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. J Infect Dis. 2004;189:1401\u201310.","journal-title":"J Infect Dis."},{"key":"3794_CR28","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1073\/pnas.88.10.4220","volume":"88","author":"LJ Walsh","year":"1991","unstructured":"Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor alpha, which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A. 1991;88:4220\u20134.","journal-title":"Proc Natl Acad Sci U S A."},{"key":"3794_CR29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","volume":"10","author":"D Lienard","year":"1992","unstructured":"Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52\u201360.","journal-title":"J Clin Oncol."},{"key":"3794_CR30","unstructured":"Lienard D, Eggermont AM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. results of a multi-centre pilot study. Melanoma Res. 1994;4(Suppl 1):21\u20136."},{"key":"3794_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1128\/CVI.00090-07","volume":"14","author":"A Garcia-Pineres","year":"2007","unstructured":"Garcia-Pineres A, Hildesheim A, Dodd L, et al. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 virus-like particles. Clin Vaccine Immunol. 2007;14:984\u20139.","journal-title":"Clin Vaccine Immunol."},{"key":"3794_CR32","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1007\/s00262-011-1162-8","volume":"61","author":"SN Karagiannis","year":"2012","unstructured":"Karagiannis SN, Josephs DH, Karagiannis P, et al. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application. Cancer Immunol Immunother. 2012;61:1547\u201364.","journal-title":"Cancer Immunol Immunother."},{"key":"3794_CR33","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1084\/jem.169.4.1295","volume":"169","author":"D Vercelli","year":"1989","unstructured":"Vercelli D, Jabara HH, Arai K, Geha RS. Induction of human IgE synthesis requires interleukin 4 and T\/B cell interactions involving the T cell receptor\/CD3 complex and MHC class II antigens. J Exp Med. 1989;169:1295\u2013307.","journal-title":"J Exp Med."},{"key":"3794_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/sj.bjc.6600043","volume":"86","author":"J Atzpodien","year":"2002","unstructured":"Atzpodien J, Neuber K, Kamanabrou D, et al. Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the cooperative advanced malignant melanoma chemoimmunotherapy group (ACIMM). Br J Cancer. 2002;86:179\u201384.","journal-title":"Br J Cancer."},{"key":"3794_CR35","doi-asserted-by":"publisher","first-page":"4474","DOI":"10.1200\/JCO.2004.10.212","volume":"22","author":"CL Slingluff Jr","year":"2004","unstructured":"Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474\u201385.","journal-title":"J Clin Oncol."},{"key":"3794_CR36","doi-asserted-by":"publisher","first-page":"7440","DOI":"10.1158\/1078-0432.CCR-11-1650","volume":"17","author":"GR Weiss","year":"2011","unstructured":"Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res. 2011;17:7440\u201350.","journal-title":"Clin Cancer Res."},{"key":"3794_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1089\/cbr.2007.0438","volume":"23","author":"EG Elias","year":"2008","unstructured":"Elias EG, Zapas JL, McCarron EC, Beam SL, Hasskamp JH, Culpepper WJ. Sequential administration of GM-CSF (sargramostim) and IL-2 +\/\u2212 autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother Radiopharm. 2008;23:285\u201391.","journal-title":"Cancer Biother Radiopharm."},{"key":"3794_CR38","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","volume":"17","author":"MB Atkins","year":"1999","unstructured":"Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105\u201316.","journal-title":"J Clin Oncol."},{"key":"3794_CR39","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archsurg.140.9.865","volume":"140","author":"TG Zogakis","year":"2005","unstructured":"Zogakis TG, Essner R, Wang HJ, et al. Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg. 2005;140:865\u201371.","journal-title":"Arch Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-014-3794-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3794-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-3794-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:34:24Z","timestamp":1684866864000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-014-3794-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,20]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["3794"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-3794-3","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,20]]},"assertion":[{"value":"4 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2014","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}